Patents Examined by Bruck Kifle
-
Patent number: 11986531Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.Type: GrantFiled: July 28, 2021Date of Patent: May 21, 2024Assignees: Arvinas Operations, Inc., Yale UniversityInventors: Andrew P. Crew, Keith R. Hornberger, Jing Wang, Saul Jaime-Figueroa, Hanqing Dong, Kurt Zimmermann, Craig M. Crews
-
Patent number: 11980619Abstract: Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection. The compositions may be administered intact, or may be crushed prior to administration.Type: GrantFiled: July 28, 2022Date of Patent: May 14, 2024Assignee: NANOCOPOEIA, LLCInventors: Christian F. Wertz, Tzehaw Chen
-
Patent number: 11981687Abstract: The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.Type: GrantFiled: June 15, 2022Date of Patent: May 14, 2024Assignee: IMMUNOGEN, INC.Inventors: Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
-
Patent number: 11981688Abstract: The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.Type: GrantFiled: June 15, 2022Date of Patent: May 14, 2024Assignee: IMMUNOGEN, INC.Inventors: Michael Reardon, Richard A. Silva
-
Patent number: 11976078Abstract: A new class of ordered functional nanoporous material (OFNMs) with a unique combination of electronic conductivity, gas transport ability, and ion transport properties are provided. The OFNM provided is highly ordered and contains nanometer scale pores lined with nitrogen atoms. The pores have dimensions of from 1.2 nm to 82 nm of longest linear extent across the pore. The functionality within the pore is controlled through selection of groups that extend into the pore. The degree of conjugated aromaticity is readily controlled to adjust the electrical conductivity properties of the resulting structure. By adjusting the groups external to the pore, three-dimensional structures are formed that are organic mimics of zeolites, metal organic frameworks (MOF), or perovskites.Type: GrantFiled: February 28, 2017Date of Patent: May 7, 2024Assignee: UNIVERSITY OF WYOMINGInventors: Bruce Alan Parkinson, John Hoberg, Jordan Brophy
-
Patent number: 11976032Abstract: A process for preparing an S,S?-dialkyldithiocarbonate from a dialkyl disulfide and from a particular metal catalyst, in the presence of carbon monoxide is described in addition to the use of S,S?-dialkyldithiocarbonates as reagents for the preparation of polycarbonates, compounds containing at least one urea and/or isocyanate function and compounds containing at least one thioalkyl function.Type: GrantFiled: March 13, 2019Date of Patent: May 7, 2024Assignee: Arkema FranceInventors: Paul-Guillaume Schmitt, Georges Frémy, Gilles-Olivier Gratien
-
Patent number: 11976083Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.Type: GrantFiled: April 28, 2021Date of Patent: May 7, 2024Assignee: Gilead Sciences, Inc.Inventors: Eda Y. Canales, Weng K. Chang, Laurent P. Debien, Petr Jansa, Jennifer A. Loyer-Drew, Luisruben P. Martinez, Stephane Perreault, Gary B Phillips, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen
-
Patent number: 11970473Abstract: Nootkatone derivatives comprising a fused thiazole ring and methods of using the same are disclosed herein.Type: GrantFiled: March 31, 2022Date of Patent: April 30, 2024Assignee: Arkansas State University—JonesboroInventor: Mohammad Abrar Alam
-
Patent number: 11964961Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g.Type: GrantFiled: March 17, 2021Date of Patent: April 23, 2024Assignee: Pfizer Inc.Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
-
Patent number: 11958854Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.Type: GrantFiled: November 10, 2021Date of Patent: April 16, 2024Assignee: Hydra Biosciences, LLCInventors: Bertrand L. Chenard, Randall J. Gallaschun
-
Patent number: 11952344Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.Type: GrantFiled: September 25, 2020Date of Patent: April 9, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuya Oguro, Makoto Kamata, Shuhei Ikeda, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Shigemitsu Matsumoto, Hirotaka Kamitani, Takaharu Hirayama, Toshio Tanaka, Hiroshi Banno, Nobuyuki Takakura, Jinichi Yonemori, Takuya Fujimoto
-
Patent number: 11952352Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.Type: GrantFiled: January 30, 2023Date of Patent: April 9, 2024Assignee: Revolution Medicines, Inc.Inventors: Adrian L. Gill, James Cregg, Elena S. Koltun, Yang Liu
-
Patent number: 11952380Abstract: The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.Type: GrantFiled: May 6, 2022Date of Patent: April 9, 2024Assignee: LUPIN LIMITEDInventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Sachin Sethi, Dipak Raychand Lagad, Chetan Sanjay Pawar, Mahadeo Bhaskar Tryambake, Chaitanya Prabhakar Kulkarni, Anil Kashiram Hajare, Balasaheb Arjun Gore, Sanjeev Anant Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 11952389Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: May 3, 2022Date of Patent: April 9, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
-
Patent number: 11945802Abstract: Provided is an additive for imparting ultraviolet absorbency, or an additive for imparting a high refractive index, which has satisfactory compatibility with a resin serving as a matrix and can maintain high transparency even if added in high concentrations. Also provided is an additive with which the function of imparting both ultraviolet absorbency and a high refractive index can be realized by means of one kind of additive. This additive is represented by the following Formula (I): wherein at least one of R1a to R9a is a monovalent sulfur-containing group represented by the following Formula (i-1) or Formula (i-2): wherein R10a to R12a each represent a divalent hydrocarbon group or the like; and R13a represents a monovalent hydrocarbon group or the like.Type: GrantFiled: May 19, 2022Date of Patent: April 2, 2024Assignees: MIYOSHI OIL & FAT CO., LTD., TOKAI OPTICAL CO., LTD.Inventors: Koji Kawai, Kotaro Kaneko, Nobuhiro Kaneko, Yuichi Shishino, Kuniyoshi Okamoto
-
Patent number: 11944624Abstract: A method of treating cancer in a subject includes administering to the subject a therapeutically effective amount of a compound, the small molecule having a general formula: A-L-X—Z (I).Type: GrantFiled: July 3, 2018Date of Patent: April 2, 2024Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Bingcheng Wang, Bin Su, Aaron Petty
-
Patent number: 11945812Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.Type: GrantFiled: June 1, 2021Date of Patent: April 2, 2024Assignees: Boehringer Ingelheim International GmbH, Vanderbilt UniversityInventors: Jason Abbott, Joachim Broeker, Jianwen Cui, Steve W. Fesik, Andreas Gollner, Tim Hodges, Jale Karolyi-Oezguer, Andrew Little, Andreas Mantoulidis, Jason Phan, Dhruba Sarkar, Christian Alan Paul Smethurst, Qi Sun, Matthias Treu, Alex Waterson
-
Patent number: 11939300Abstract: Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of an autoimmune disease by modulating the T cell response to antigenic peptide or fragments of antigenic peptides presented by the major histocompatibility (MHC) class II molecule, DQ2.Type: GrantFiled: August 20, 2021Date of Patent: March 26, 2024Assignee: ImmunoMolecular Therapeutics, Inc.Inventors: Robert B. Perni, Ryan Schutte, James M. Siedlecki, Asha Ghevde
-
Patent number: 11939302Abstract: The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.Type: GrantFiled: October 19, 2021Date of Patent: March 26, 2024Assignee: The Governors of the University of AlbertaInventors: James A. Nieman, Jack Jhamandas, Bing Bai, Alexandr Belovodskiy, Wen Fu, Mostofa Hena, Michael Houghton, Appan Srinivas Kandadai, Ryoichi Kimura, Kamlesh Kumar Sahu, D. Lorne Tyrrell
-
Patent number: 11938138Abstract: Among the various aspects of the present disclosure is the provision of a methods for increasing chemotherapy sensitivity or decreasing chemotherapy resistance using BET inhibitors.Type: GrantFiled: July 9, 2021Date of Patent: March 26, 2024Assignee: Washington UniversityInventors: Robi Mitra, Arnav Moudgil, Michael Nathaniel Wilkinson